VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

NYVAC-JEV- prM/E/ NS1
Vaccine Information
  • Vaccine Ontology ID: VO_0004780
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • PrM gene engineering:
    • Type: Recombinant vector construction
    • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
    • Detailed Gene Information: Click Here.
  • NS1 gene engineering:
    • Type: Recombinant vector construction
    • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
    • Detailed Gene Information: Click Here.
  • E gene engineering:
    • Type: Recombinant protein preparation
    • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
    • Detailed Gene Information: Click Here.
  • Preparation: Highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Pig Response

  • Vaccination Protocol: The recombinant viruses were tested as vaccine candidates in pigs, a natural host of JEV. JEV-neutralizing and hemagglutination-inhibiting antibodies appeared in swine sera 7 days after immunization with 108 PFU of the recombinant viruses and increased after a second dose at 28 days (Konishi et al., 1992).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: JEV challenge (d56) of the swine with 2 × 108 PFU of JEV (Konishi et al., 1992).
  • Efficacy: The JEV levels detected in the serum after JEV challenge were significantly reduced in animals inoculated with the recombinant viruses (Konishi et al., 1992).
References
Konishi et al., 1992: Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, Mason PW. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology. 1992; 190(1); 454-458. [PubMed: 1326813].